Alefacept therapy produces remission for patients with chronic plaque psoriasis

被引:46
作者
Krueger, GG
Ellis, CN
机构
[1] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA
[2] Univ Utah, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT 84132 USA
关键词
alefacept; disease remission; duration of response; psoriasis;
D O I
10.1046/j.1365-2133.2003.05239.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Alefacept, human LFA-3/IgG(1) fusion protein, is a novel biological agent currently being developed for the treatment of chronic plaque psoriasis. Alefacept selectively reduces the memory-effector T cells that have been implicated in the pathogenesis of the disease; as a result, alefacept is classified as a therapy that induces remission (so-called 'remittive' therapy). In a previously published randomized, placebo-controlled phase II study of intravenous alefacept in 229 patients with chronic plaque psoriasis, clinical improvement was observed during dosing as well as in the postdosing follow-up period. Objectives To assess the remission period following alefacept therapy. Methods The time before re-treatment was required was measured in patients who were 'clear' or 'almost clear' of disease according to a physician global assessment at the end of the follow-up phase. Results In these patients, responses were sustained for a median of 10 months, and for up to 18 months. No patient reported disease rebound after cessation of alefacept. Conclusions Alefacept is a biological agent for the treatment of chronic plaque psoriasis that provides disease-free intervals and time off drug therapy.
引用
收藏
页码:784 / 788
页数:5
相关论文
共 27 条
[1]   The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [J].
Austin, LM ;
Ozawa, M ;
Kikuchi, T ;
Walters, IB ;
Krueger, JG .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :752-759
[2]  
CACOUB P, 1988, LANCET, V2, P219
[3]  
Chisholm P L, 1994, Ther Immunol, V1, P205
[4]   Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris - Evidence that epidermal immunocytes are direct therapeutic targets [J].
Coven, TR ;
Murphy, FP ;
Gilleaudeau, P ;
Cardinale, I ;
Krueger, JG .
ARCHIVES OF DERMATOLOGY, 1998, 134 (10) :1263-1268
[5]  
ELLIS C, 2001, J EUR ACAD DERMAT S2, V15, P246
[6]   Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes [J].
Ellis, CN ;
Krueger, GG .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04) :248-255
[7]   CYCLOSPORINE FOR PLAQUE-TYPE PSORIASIS - RESULTS OF A MULTIDOSE, DOUBLE-BLIND TRIAL [J].
ELLIS, CN ;
FRADIN, MS ;
MESSANA, JM ;
BROWN, MD ;
SIEGEL, MT ;
HARTLEY, AH ;
ROCHER, LL ;
WHEELER, S ;
HAMILTON, TA ;
PARISH, TG ;
ELLISMADU, M ;
DUELL, E ;
ANNESLEY, TM ;
COOPER, KD ;
VOORHEES, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (05) :277-284
[8]  
*FOOD DRUG ADM, 2002, AM AL BRIEF DOC
[9]   Flow cytometric characterization of lesional T cells in psoriasis:: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype [J].
Friedrich, M ;
Krammig, S ;
Henze, M ;
Döcke, WD ;
Sterry, W ;
Asadullah, K .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2000, 292 (10) :519-521
[10]   Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapy [J].
Georgala, S ;
Koumantaki, E ;
Rallis, E ;
Papadavid, E .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 142 (05) :1057-1058